JP2020533347A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533347A5 JP2020533347A5 JP2020514579A JP2020514579A JP2020533347A5 JP 2020533347 A5 JP2020533347 A5 JP 2020533347A5 JP 2020514579 A JP2020514579 A JP 2020514579A JP 2020514579 A JP2020514579 A JP 2020514579A JP 2020533347 A5 JP2020533347 A5 JP 2020533347A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halogen
- hydrogen
- cycloalkyl
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 139
- 239000001257 hydrogen Substances 0.000 claims description 131
- 229910052736 halogen Inorganic materials 0.000 claims description 128
- 150000002367 halogens Chemical class 0.000 claims description 128
- 125000005843 halogen group Chemical group 0.000 claims description 95
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 91
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 80
- 150000002431 hydrogen Chemical class 0.000 claims description 75
- 150000001875 compounds Chemical class 0.000 claims description 56
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 54
- 229910052760 oxygen Inorganic materials 0.000 claims description 52
- 125000005842 heteroatom Chemical group 0.000 claims description 46
- -1 C 2 to C 6 alkynyl Chemical group 0.000 claims description 45
- 229910052717 sulfur Inorganic materials 0.000 claims description 41
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 35
- 125000000623 heterocyclic group Chemical group 0.000 claims description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 125000004043 oxo group Chemical group O=* 0.000 claims description 24
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 22
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 12
- 206010019280 Heart failures Diseases 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 125000006413 ring segment Chemical group 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000003003 spiro group Chemical group 0.000 claims description 10
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 208000019622 heart disease Diseases 0.000 claims description 8
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 8
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 7
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 7
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 230000002107 myocardial effect Effects 0.000 claims description 6
- 125000003566 oxetanyl group Chemical group 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 125000002393 azetidinyl group Chemical group 0.000 claims description 5
- 125000001963 4 membered heterocyclic group Chemical group 0.000 claims description 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 229940127557 pharmaceutical product Drugs 0.000 claims description 4
- 102000003505 Myosin Human genes 0.000 claims description 3
- 108060008487 Myosin Proteins 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims description 2
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical group C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims description 2
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical group NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 208000008253 Systolic Heart Failure Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000005605 benzo group Chemical group 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 238000000034 method Methods 0.000 description 17
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762557846P | 2017-09-13 | 2017-09-13 | |
| US62/557,846 | 2017-09-13 | ||
| PCT/US2018/050793 WO2019055590A1 (en) | 2017-09-13 | 2018-09-13 | SARCOMERIC BISAMIDE ACTIVATOR COMPOUNDS AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533347A JP2020533347A (ja) | 2020-11-19 |
| JP2020533347A5 true JP2020533347A5 (enExample) | 2021-10-21 |
| JP7308816B2 JP7308816B2 (ja) | 2023-07-14 |
Family
ID=63794635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514579A Active JP7308816B2 (ja) | 2017-09-13 | 2018-09-13 | ビスアミド筋節活性化化合物及びその使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US10723720B2 (enExample) |
| EP (1) | EP3681882A1 (enExample) |
| JP (1) | JP7308816B2 (enExample) |
| KR (1) | KR20200054237A (enExample) |
| CN (1) | CN111601798B (enExample) |
| AR (1) | AR112804A1 (enExample) |
| AU (1) | AU2018332887B2 (enExample) |
| BR (1) | BR112020004800A2 (enExample) |
| CA (1) | CA3075669A1 (enExample) |
| CL (1) | CL2020000610A1 (enExample) |
| CO (1) | CO2020002745A2 (enExample) |
| CR (1) | CR20200116A (enExample) |
| EA (1) | EA202090688A1 (enExample) |
| IL (1) | IL272573B2 (enExample) |
| JO (1) | JOP20200059A1 (enExample) |
| MA (1) | MA50173A (enExample) |
| MX (2) | MX2020002696A (enExample) |
| PE (1) | PE20200924A1 (enExample) |
| PH (1) | PH12020500446A1 (enExample) |
| SA (1) | SA520411524B1 (enExample) |
| SG (1) | SG11202001377PA (enExample) |
| TW (1) | TWI790281B (enExample) |
| UY (1) | UY37879A (enExample) |
| WO (1) | WO2019055590A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY37879A (es) | 2017-09-13 | 2019-03-29 | Amgen Inc | Compuestos de bisamida que activan el sarcómero y sus usos |
| CN118373875A (zh) * | 2018-05-29 | 2024-07-23 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| JP2022524609A (ja) | 2019-03-12 | 2022-05-09 | アムジェン インコーポレイテッド | 心臓トロポニン活性化因子の多形及び共結晶 |
| EP3938042A1 (en) * | 2019-03-12 | 2022-01-19 | Amgen Inc. | Polymorphs of a cardiac troponin activator |
| US12610949B2 (en) * | 2019-07-23 | 2026-04-28 | Bayer Aktiengesellschaft | Heteroaryl-triazole compounds as pesticides |
| KR20220110531A (ko) | 2019-12-04 | 2022-08-08 | 오메로스 코포레이션 | Masp-2 억제자 및 사용 방법 |
| KR20220110529A (ko) | 2019-12-04 | 2022-08-08 | 오메로스 코포레이션 | Masp-2 억제자 및 사용 방법 |
| WO2021113682A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| WO2021113698A1 (en) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Masp-2 inhibitors and methods of use |
| JP7323723B2 (ja) * | 2020-06-17 | 2023-08-08 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド |
| WO2022198196A1 (en) | 2021-03-15 | 2022-09-22 | Maze Therapeutics, Inc. | Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof |
| WO2023122325A2 (en) * | 2021-12-23 | 2023-06-29 | Regents Of The University Of Michigan | Meta anilide compounds and methods for use of the same to treat diseases and disorders |
| IL319671A (en) | 2022-09-26 | 2025-05-01 | Edgewise Therapeutics Inc | 4,1-Dihydroquinazolinone compounds and their uses |
| JP7858148B1 (ja) | 2023-03-27 | 2026-05-13 | エッジワイズ セラピューティクス， インコーポレイテッド | キナゾリンジオン化合物およびその使用 |
| EP4688748A1 (en) | 2023-03-27 | 2026-02-11 | Edgewise Therapeutics, Inc. | Quinolinone amide compounds and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0662529B2 (ja) | 1984-07-13 | 1994-08-17 | 三共株式会社 | アミノ酸誘導体 |
| US5952307A (en) | 1994-01-21 | 1999-09-14 | Georgia Tech Research Corp. | Basic α-aminoalkylphosphonate derivatives |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| GB9708119D0 (en) | 1997-04-22 | 1997-06-11 | Glaxo Group Ltd | Chemical compounds |
| AU1082901A (en) | 1999-10-18 | 2001-04-30 | National Jewish Medical And Research Center | Method for modulation of cell phenotype |
| US20010049373A1 (en) | 2000-01-28 | 2001-12-06 | Chalquest Richard R. | Materials and methods for killing nematodes and nematode eggs |
| EP1125925A1 (en) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
| US6495337B1 (en) | 2000-03-29 | 2002-12-17 | Cytokinetics, Inc. | High throughput sarcomeric assay |
| JP2004528822A (ja) | 2000-11-07 | 2004-09-24 | ボード・オブ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム | 筋特異的筋節カルシニューリン結合タンパク質（カルサルシン）に関する方法および組成物 |
| US20030158186A1 (en) | 2001-12-21 | 2003-08-21 | Fady Malik | Compositions and methods for treating heart failure |
| US6908923B2 (en) | 2001-12-21 | 2005-06-21 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| CA2511970C (en) | 2003-01-14 | 2012-06-26 | Cytokinetics, Inc. | Urea derivatives useful in the treatment of heart failure |
| US7595322B2 (en) | 2003-03-27 | 2009-09-29 | Cytokinetics, Inc. | Heterocyclic sulfonamides as modulators of cardiac sarcomeres |
| US20050043260A1 (en) | 2003-04-21 | 2005-02-24 | Baylor College Of Medicine | Wnt as a factor for cardiac myogenesis |
| US7541466B2 (en) | 2003-12-23 | 2009-06-02 | Genzyme Corporation | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases |
| JP2005298628A (ja) | 2004-04-09 | 2005-10-27 | Sumitomo Chemical Co Ltd | オレフィン重合触媒成分及びオレフィン重合体の製造方法 |
| BRPI0512193B8 (pt) | 2004-06-17 | 2021-05-25 | Cytokinetics Inc | composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal |
| US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| US20070208000A1 (en) | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| ES2419007T3 (es) | 2005-12-15 | 2013-08-19 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y procedimientos |
| US7718657B2 (en) | 2005-12-16 | 2010-05-18 | Cytokinetics, Inc. | Certain indanyl urea modulators of the cardiac sarcomere |
| EP1962852B1 (en) | 2005-12-19 | 2017-01-25 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2007089805A2 (en) | 2006-01-31 | 2007-08-09 | The General Hospital Corporation | Anti-hypertrophic effects and inotropic effects of picot |
| US20080227823A1 (en) | 2007-03-12 | 2008-09-18 | Hassan Pajouhesh | Amide derivatives as calcium channel blockers |
| GB0708818D0 (en) | 2007-05-08 | 2007-06-13 | Portela & Ca Sa | Compounds |
| US20090192168A1 (en) * | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| CN104024249A (zh) | 2011-10-17 | 2014-09-03 | 埃南塔制药公司 | 丙型肝炎病毒抑制剂 |
| WO2013106646A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| JP2015508414A (ja) * | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| AU2014240104B2 (en) | 2013-03-14 | 2018-11-08 | Amgen Inc. | Heterocyclic compounds and their uses |
| WO2015103527A1 (en) | 2014-01-06 | 2015-07-09 | The Scripps Research Institute | Modulators of rev-erb |
| WO2015142001A2 (ko) | 2014-03-21 | 2015-09-24 | 충남대학교산학협력단 | 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물 |
| PH12021553074A1 (en) | 2015-01-22 | 2023-03-06 | Myokardia Inc | 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm) |
| JP7269731B2 (ja) | 2015-03-18 | 2023-05-09 | アルビナス・オペレーションズ・インコーポレイテッド | 標的タンパク質の分解向上のための化合物および方法 |
| US10829440B2 (en) | 2015-06-12 | 2020-11-10 | Brown University | Antibacterial compounds and methods of making and using same |
| KR101766731B1 (ko) | 2015-06-23 | 2017-08-10 | 충남대학교산학협력단 | 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물 |
| US10543215B2 (en) | 2015-06-26 | 2020-01-28 | Amgen Inc. | Combination therapy of cardiac myosin activator and sinus node if current inhibitor |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| KR20160108281A (ko) | 2016-09-06 | 2016-09-19 | 충남대학교산학협력단 | 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물 |
| US11040956B2 (en) | 2017-06-30 | 2021-06-22 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| UY37879A (es) | 2017-09-13 | 2019-03-29 | Amgen Inc | Compuestos de bisamida que activan el sarcómero y sus usos |
| HUE052049T2 (hu) | 2018-07-09 | 2021-04-28 | Fis Fabbrica Italiana Sintetici Spa | Kristályos 2-fluor-3-nitrotoluol és eljárás annak elõállítására |
| JP2021534138A (ja) | 2018-08-17 | 2021-12-09 | アムジエン・インコーポレーテツド | オメカムチブメカルビルの塩及び結晶形態 |
| WO2020131574A1 (en) | 2018-12-18 | 2020-06-25 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| EP3938042A1 (en) | 2019-03-12 | 2022-01-19 | Amgen Inc. | Polymorphs of a cardiac troponin activator |
| JP2022524609A (ja) | 2019-03-12 | 2022-05-09 | アムジェン インコーポレイテッド | 心臓トロポニン活性化因子の多形及び共結晶 |
-
2018
- 2018-09-13 UY UY0001037879A patent/UY37879A/es not_active Application Discontinuation
- 2018-09-13 AU AU2018332887A patent/AU2018332887B2/en not_active Ceased
- 2018-09-13 AR ARP180102603A patent/AR112804A1/es unknown
- 2018-09-13 US US16/129,862 patent/US10723720B2/en active Active
- 2018-09-13 CN CN201880072907.5A patent/CN111601798B/zh active Active
- 2018-09-13 WO PCT/US2018/050793 patent/WO2019055590A1/en not_active Ceased
- 2018-09-13 MX MX2020002696A patent/MX2020002696A/es unknown
- 2018-09-13 IL IL272573A patent/IL272573B2/en unknown
- 2018-09-13 PE PE2020000339A patent/PE20200924A1/es unknown
- 2018-09-13 CR CR20200116A patent/CR20200116A/es unknown
- 2018-09-13 EP EP18783202.7A patent/EP3681882A1/en not_active Withdrawn
- 2018-09-13 KR KR1020207010115A patent/KR20200054237A/ko not_active Abandoned
- 2018-09-13 MA MA050173A patent/MA50173A/fr unknown
- 2018-09-13 JP JP2020514579A patent/JP7308816B2/ja active Active
- 2018-09-13 SG SG11202001377PA patent/SG11202001377PA/en unknown
- 2018-09-13 JO JOP/2020/0059A patent/JOP20200059A1/ar unknown
- 2018-09-13 CA CA3075669A patent/CA3075669A1/en active Pending
- 2018-09-13 TW TW107132171A patent/TWI790281B/zh active
- 2018-09-13 BR BR112020004800-3A patent/BR112020004800A2/pt not_active Application Discontinuation
- 2018-09-13 EA EA202090688A patent/EA202090688A1/ru unknown
-
2020
- 2020-03-05 PH PH12020500446A patent/PH12020500446A1/en unknown
- 2020-03-10 CL CL2020000610A patent/CL2020000610A1/es unknown
- 2020-03-10 MX MX2022014864A patent/MX2022014864A/es unknown
- 2020-03-10 CO CONC2020/0002745A patent/CO2020002745A2/es unknown
- 2020-03-12 SA SA520411524A patent/SA520411524B1/ar unknown
- 2020-03-27 US US16/833,336 patent/US10899746B2/en active Active
- 2020-03-27 US US16/833,321 patent/US11254658B2/en not_active Expired - Fee Related
- 2020-10-12 US US17/068,518 patent/US11299479B1/en not_active Expired - Fee Related
-
2022
- 2022-02-15 US US17/672,594 patent/US11780826B2/en active Active
-
2023
- 2023-08-17 US US18/451,757 patent/US20240158372A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100728665B1 (ko) | 함질소 복소환 화합물 및 그 의약 | |
| KR101768946B1 (ko) | 프롤린 유도체 | |
| TWI461423B (zh) | 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物 | |
| KR102653667B1 (ko) | Apj 수용체의 트라이아졸 작용제 | |
| US11098010B2 (en) | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same | |
| JP4719745B2 (ja) | カリウムチャンネル阻害剤 | |
| JP6535034B2 (ja) | アミノピラン環誘導体及びその組成物と用途 | |
| JP2019525941A (ja) | ジメトキシフェニル置換インドール化合物 | |
| JP2005508960A5 (enExample) | ||
| JP2005508967A5 (enExample) | ||
| BR112020015583A2 (pt) | composto, composição farmacêutica, e, métodos para inibir a atividade de prc2 em uma célula e para tratar câncer | |
| TWI801517B (zh) | 經取代的2-吡啶酮三環化合物、其類似物及其使用方法 | |
| JP3981406B2 (ja) | ５−ｈｔ４レセプター拮抗薬 | |
| WO2021119081A1 (en) | Hepatitis b capsid assembly modulators | |
| JP2023513373A (ja) | Ｐ２ｘ３修飾薬 | |
| KR20150120516A (ko) | 2-아실아미노티아졸 유도체 또는 그의 염 | |
| JP2021500332A5 (enExample) | ||
| JP2005500276A5 (enExample) | ||
| JP4542757B2 (ja) | 縮合複素環化合物 | |
| JP5892550B2 (ja) | 縮合イミダゾール誘導体 | |
| JPWO2002072564A1 (ja) | Ｎ−フェニル−アリールスルフォンアミド化合物、その化合物を有効成分として含有する薬剤、その化合物の合成中間体およびその製造方法 | |
| JP2007530582A (ja) | 代謝可能部分を含む複素環抗ウイルス化合物およびその使用 | |
| KR101303348B1 (ko) | 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물 | |
| JP2009514801A5 (enExample) | ||
| EP1757602A1 (en) | Vla-4 inhibitor |